Legal & General Group PLC Immuneering Corp Transaction History

Legal & General Group PLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 15, 2024	SELL	$4.84 - $8.44 $2,303 - $4,017	-476 Reduced 18.0%	2,168 $15,000
Q3 2023 Nov 14, 2023	BUY	$7.21 - $10.68 $2,177 - $3,225	302 Added 12.89%	2,644 $20,000
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $15,199 - $31,289	2,342 New	2,342 $23,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $14.32 $7,955 - $22,783	-1,591 Closed	0 $0
Q2 2022 Aug 22, 2022	SELL	$3.89 - $7.81 $1,054 - $2,116	-271 Reduced 14.55%	1,591 $9,000
Q1 2022 May 16, 2022	BUY	$6.47 - $16.99 $7,039 - $18,485	1,088 Added 140.57%	1,862 $12,000
Q3 2021 Nov 15, 2021	BUY	$17.0 - $32.84 $13,158 - $25,418	774 New	774 $20,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $55.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.